Objective To compare the clinical efficacy of low-dose urokinase combined with heparin and warfarin with that of heparin in combination of warfarin for pulmonary embolism.Methods 62 patients with pulmonary embolism confirmed in our hospital were randomly divided into a study group and a control group.Both groups received combination therapy with heparin and warfarin,while the group received additionallow-dose urokinase.The relief rate of symptoms and the efficacy were compared between the two groups.Results The relief rates of dyspnea,cough,and chest pain were 93.5％,82.6％,and 80.8％ in the study group and 77.4％,47.6％,and 53.8％ in the control group,with a significant difference between the two groups (P＜0.05).The effectiveness rarte was significantly higher in the study group than in the control group (17 patients vs.12 patients for cure,12 vs.10 for improvement,and 2 vs.9 for unresponsiveness; P＜ 0.05).Conclusions Low-dose urokinase combined with heparin and warfarin is superior to heparin and warfarin alone for pulmonary embolism,and it is worth popularizing.%目的 比较小剂量尿激酶溶栓联合肝素和华法林抗凝治疗肺栓塞与肝素联合华法林抗凝治疗肺栓塞的临床疗效.方法 将本院确诊的62例肺栓塞病人随机分为实验组与对照组,两组患者均给予肝素与华法林的联合治疗,实验组患者在此基础上给予小剂量尿激酶,比较两组患者的症状缓解情况及临床疗效.结果 实验组患者呼吸困难、咳嗽、胸痛等症状缓解率分别为93.5％、82.6％、80.8％,而对照组为77.4％、47.6％、53.8％,实验组症状缓解显著优于对照组(P＜0.05).实验组患者治愈、好转、无效的例数分别为17例、12例、2例,而对照组为12例、10例、9例,实验组治疗有效率显著高于对照组(P＜0.05).结论 小剂量尿激酶溶栓联合肝素和华法林抗凝治疗对于肺栓塞的临床疗效优于单纯抗凝治疗,值得推广应用.
展开▼
